<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35387545</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1525-6049</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>44</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Renal failure</Title>
          <ISOAbbreviation>Ren Fail</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Iguratimod alleviates tubulo-interstitial injury in mice with lupus.</ArticleTitle>
        <Pagination>
          <StartPage>636</StartPage>
          <EndPage>647</EndPage>
          <MedlinePgn>636-647</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/0886022X.2022.2058962</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Tubulo-interstitial injury is a poor prognostic factor for lupus nephritis (LN). Here, we tested whether iguratimod could inhibit tubulo-interstitial injury in LN.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="UNASSIGNED">MRL/lpr mice, an animal model of lupus, were treated with iguratimod or vehicle solution. Pathological changes of kidney were evaluated blindly by the same pathologist. Renal type I collagen (COL-I), IgG, E-cadherin, fibroblast-specific protein 1 (FSP-1) were detected by immunofluorescence, immunohistochemical staining or quantitative real-time PCR. After treated with transforming growth factor β1 (TGF-β1) and iguratimod, E-cadherin, fibronectin, Smad2/3, p38 MAPK, p-Smad2/3, and p-p38 MAPK, β-catenin and TGF-β type II receptor (TGFβRII) in HK2 cells were measured by western blotting, quantitative real-time PCR or immunofluorescence.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Iguratimod reduced immune deposition along the tubular basement membrane, inhibited the tubulo-interstitial infiltration of inflammatory cells, and alleviated tubular injury in MRL/lpr mice. Moreover, Iguratimod eased the tubulo-interstitial deposition of collagen fibers, which was confirmed by decreased expression of COL-I. Furthermore, iguratimod suppressed the expression of FSP-1 and increased that of E-cadherin in renal tubular epithelial cells. In HK2 cells cultured with TGF-β1, iguratimod treatment not only reversed cellular morphological changes, but also prevented E-cadherin downregulation and fibronectin upregulation. In addition, iguratimod inhibited phosphorylation of TGFβRII, Smad2/3 and p38 MAPK in HK2 cells treated with TGF-β1, and also blocked nuclear translocation of β-catenin.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Iguratimod eased tubulo-interstitial lesions in LN, especially tubulo-interstitial fibrosis, and might have potential as a drug for inhibiting the progression of tubulo-interstitial fibrosis in LN.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xue</LastName>
            <ForeName>Leixi</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Jiajun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Wentian</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fu</LastName>
            <ForeName>Jinxiang</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Zhichun</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ren Fail</MedlineTA>
        <NlmUniqueID>8701128</NlmUniqueID>
        <ISSNLinking>0886-022X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015820">Cadherins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002867">Chromones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005353">Fibronectins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4IHY34Y2NV</RegistryNumber>
          <NameOfSubstance UI="C519076">iguratimod</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015820" MajorTopicYN="N">Cadherins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002867" MajorTopicYN="N">Chromones</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005353" MajorTopicYN="N">Fibronectins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005355" MajorTopicYN="N">Fibrosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019463" MajorTopicYN="N">Mice, Inbred MRL lpr</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053773" MajorTopicYN="Y">Transforming Growth Factor beta1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051176" MajorTopicYN="N">beta Catenin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048051" MajorTopicYN="N">p38 Mitogen-Activated Protein Kinases</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Iguratimod</Keyword>
        <Keyword MajorTopicYN="N">epithelial-to-mesenchymal transition</Keyword>
        <Keyword MajorTopicYN="N">lupus nephritis</Keyword>
        <Keyword MajorTopicYN="N">renal interstitial fibrosis</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>5</Hour>
          <Minute>26</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35387545</ArticleId>
        <ArticleId IdType="pmc">PMC9004506</ArticleId>
        <ArticleId IdType="doi">10.1080/0886022X.2022.2058962</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Tsokos GC, Lo MS, Costa Reis P, et al. . 
New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716–730.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27872476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anders HJ, Saxena R, Zhao MH, et al. . 
Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31974366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yung S, Chan TM.. 
Molecular and immunological basis of tubulo-Interstitial injury in lupus nephritis: a comprehensive review. Clin Rev Allergy Immunol. 2017;52(2):149–163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26961386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aikawa Y, Yamamoto M, Yamamoto T, et al. . 
An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflamm Res. 2002;51(4):188–194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12058956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inaba T, Tanaka K, Takeno R, et al. . 
Synthesis and antiinflammatory activity of 7-methanesulfonylamino-6-phenoxychromones. Antiarthritic effect of the 3-formylamino compound (T-614) in chronic inflammatory disease models. Chem Pharm Bull (Tokyo)). 2000;48(1):131–139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10705489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lau CS, Chia F, Dans L, et al. . 
2018 Update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis. 2019;22(3):357–375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30809944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li G, Yamasaki R, Fang M, et al. . 
Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-κB pathway. Sci Rep. 2018;8(1):1933.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5792543</ArticleId>
            <ArticleId IdType="pubmed">29386552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang XP, Huang XL, Yang ZP, et al. . 
Iguratimod ameliorates inflammatory responses by modulating the Th17/treg paradigm in dextran sulphate sodium-induced murine colitis. Mol Immunol. 2018;93:9–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29121519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan Q, Du F, Huang X, et al. . 
Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL/lpr mice. PLoS One. 2014;9(10):e108273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4182720</ArticleId>
            <ArticleId IdType="pubmed">25271634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corna D, Morigi M, Facchinetti D, et al. . 
Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int. 1997;51(5):1583–1589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9150476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia Y, Campbell SR, Broder A, et al. . 
Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. Clin Immunol. 2012;145(2):108–121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3483377</ArticleId>
            <ArticleId IdType="pubmed">22982296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia Y, Herlitz LC, Gindea S, et al. . 
Deficiency of fibroblast growth factor-inducible 14 (Fn14) preserves the filtration barrier and ameliorates lupus nephritis. J Am Soc Nephrol. 2015;26(5):1053–1070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4413761</ArticleId>
            <ArticleId IdType="pubmed">25270074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan X, Li Y, Liu Y.. 
Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol. 2006;17(12):3382–3393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17082242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yung S, Chan TM.. 
Anti-dsDNA antibodies and resident renal cells – their putative roles in pathogenesis of renal lesions in lupus nephritis. Clin Immunol. 2017;185:40–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27612436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yung S, Tsang RC, Sun Y, et al. . 
Effect of human anti-DNA antibodies on proximal renal tubular epithelial cell cytokine expression: implications on tubulointerstitial inflammation in lupus nephritis. JASN. 2005;16(11):3281–3294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16192422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ortiz A, Lorz C, Justo P, et al. . 
Contribution of apoptotic cell death to renal injury. J Cell Mol Med. 2001;5(1):18–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6737749</ArticleId>
            <ArticleId IdType="pubmed">12067448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rastaldi MP, Ferrario F, Giardino L, et al. . 
Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int. 2002;62(1):137–146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12081572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eddy AA.
Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol. 1996;7(12):2495–2508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8989727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y.
Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol. 2004;15(1):1–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14694152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wynn TA.
Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199–210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2693329</ArticleId>
            <ArticleId IdType="pubmed">18161745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Böttinger EP, Bitzer M.. 
TGF-beta signaling in renal disease. J Am Soc Nephrol. 2002;13(10):2600–2610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12239251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts AB, Heine UI, Flanders KC, et al. . 
Transforming growth factor-beta. Major role in regulation of extracellular matrix. Ann NY Acad Sci. 1990;580:225–232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2186691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moustakas A, Souchelnytskyi S, Heldin CH.. 
Smad regulation in TGF-beta signal transduction. J Cell Sci. 2001;114(Pt 24):4359–4369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11792802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chin BY, Mohsenin A, Li SX, et al. . 
Stimulation of pro-alpha(1)(I) collagen by TGF-beta(1) in mesangial cells: role of the p38 MAPK pathway. Am J Physiol Renal Physiol. 2001;280(3):F495–504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11181412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Z, Xue L, Liu Z, et al. . 
Tumor necrosis Factor-Like weak inducer of apoptosis accelerates the progression of renal fibrosis in lupus nephritis by activating SMAD and p38 MAPK in TGF-β1 signaling pathway. Mediators Inflamm. 2016;2016(8986451):8986451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4913011</ArticleId>
            <ArticleId IdType="pubmed">27365897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong Y, Qin Z, Zhou B, et al. . 
MicroRNA-200a inhibits transforming growth factor β1-Induced proximal tubular Epithelial-Mesenchymal transition by targeting β-Catenin. Nephron. 2017;137(3):237–249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28817830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park SH, Cho HJ, Jeong YJ, et al. . 
Melittin inhibits TGF-β-induced pro-fibrotic gene expression through the suppression of the TGFβRII-Smad, ERK1/2 and JNK-mediated signaling pathway. Am J Chin Med. 2014;42(5):1139–1152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25178280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie S, Li S, Tian J, et al. . 
Iguratimod as a new drug for rheumatoid arthritis: Current landscape. Front Pharmacol. 2020;11:73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7054862</ArticleId>
            <ArticleId IdType="pubmed">32174824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baelde HJ, Eikmans M, van Vliet AI, et al. . 
Alternatively spliced isoforms of fibronectin in immune-mediated glomerulosclerosis: the role of TGFbeta and IL-4. J Pathol. 2004;204(3):248–257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15372454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yung S, Zhang Q, Chau MK, et al. . 
Distinct effects of mycophenolate mofetil and cyclophosphamide on renal fibrosis in NZBWF1/J mice. Autoimmunity. 2015;48(7):471–487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26099989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yung S, Zhang Q, Zhang CZ, et al. . 
Anti-DNA antibody induction of protein kinase C phosphorylation and fibronectin synthesis in human and murine lupus and the effect of mycophenolic acid. Arthritis Rheum. 2009;60(7):2071–2082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19565476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yung S, Ng CY, Ho SK, et al. . 
Anti-dsDNA antibody induces soluble fibronectin secretion by proximal renal tubular epithelial cells and downstream increase of TGF-β1 and collagen synthesis. J Autoimmun. 2015;58:111–122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25666976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bajema IM, Wilhelmus S, Alpers CE, et al. . 
Revision of the international society of nephrology/renal pathology society classification for lupus nephritis: clarification of definitions, and modified national institutes of health activity and chronicity indices. Kidney Int. 2018;93(4):789–796.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29459092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Djudjaj S, Martin IV, Buhl EM, et al. . 
Macrophage migration inhibitory factor limits renal inflammation and fibrosis by counteracting tubular cell cycle arrest. J Am Soc Nephrol. 2017;28(12):3590–3604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5698074</ArticleId>
            <ArticleId IdType="pubmed">28801314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kassianos AJ, Wang X, Sampangi S, et al. . 
Increased tubulointerstitial recruitment of human CD141(hi) CLEC9A(+) and CD1c(+) myeloid dendritic cell subsets in renal fibrosis and chronic kidney disease. Am J Physiol Renal Physiol. 2013;305(10):F1391–401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24049150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kong W, Haschler TN, Nürnberg B, et al. . 
Renal fibrosis, immune cell infiltration and changes of TRPC channel expression after unilateral ureteral obstruction in Trpc6−/− mice. Cell Physiol Biochem. 2019;52:1484–1502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31099508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin DD, Luo JH, Zhao ZY, et al. . 
Tranilast prevents renal interstitial fibrosis by blocking mast cell infiltration in a rat model of diabetic kidney disease. Mol Med Rep. 2018;17:7356–7364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29568954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, Mu L, Xing L, et al. . 
Rhein alleviates renal interstitial fibrosis by inhibiting tubular cell apoptosis in rats. Biol Res. 2019;52(1):50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6728983</ArticleId>
            <ArticleId IdType="pubmed">31492196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rastaldi MP.
Epithelial-mesenchymal transition and its implications for the development of renal tubulointerstitial fibrosis. J Nephrol. 2006;19:407–412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17048197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eddy AA.
Molecular basis of renal fibrosis. Pediatr Nephrol. 2000;15(3-4):290–301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11149129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nath KA.
Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis. 1992;20(1):1–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1621674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y.
New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol. 2010;21(2):212–222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4554339</ArticleId>
            <ArticleId IdType="pubmed">20019167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang J, Liu Y.. 
Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol. 2001;159(4):1465–1475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1850509</ArticleId>
            <ArticleId IdType="pubmed">11583974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwano M, Plieth D, Danoff TM, et al. . 
Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest. 2002;110(3):341–350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC151091</ArticleId>
            <ArticleId IdType="pubmed">12163453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Border WA, Noble NA.. 
Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331(19):1286–1292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7935686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu G, Cooley MA, Jarnicki AG, et al. . 
Fibulin-1c regulates transforming growth factor-β activation in pulmonary tissue fibrosis. JCI Insight. 2019;4(16):e124529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6777837</ArticleId>
            <ArticleId IdType="pubmed">31343988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wermuth PJ, Mendoza FA, Jimenez SA.. 
Abrogation of transforming growth factor-β-induced tissue fibrosis in mice with a global genetic deletion of Nox4. Lab Invest. 2019;99(4):470–482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6530913</ArticleId>
            <ArticleId IdType="pubmed">30470772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He W, Dai C, Li Y, et al. . 
Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol. 2009;20(4):765–776.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2663839</ArticleId>
            <ArticleId IdType="pubmed">19297557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masszi A, Fan L, Rosivall L, et al. . 
Integrity of cell-cell contacts is a critical regulator of TGF-beta 1-induced epithelial-to-myofibroblast transition: role for beta-catenin. Am J Pathol. 2004;165(6):1955–1967.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1618715</ArticleId>
            <ArticleId IdType="pubmed">15579439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng G, Lyons JG, Tan TK, et al. . 
Disruption of E-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factor-beta1 in renal tubular epithelial cells. Am J Pathol. 2009;175(2):580–591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2716958</ArticleId>
            <ArticleId IdType="pubmed">19590041</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
